Central precocious puberty: an Endocrine Society clinical practice guideline
The Journal of Clinical Endocrinology & Metabolism · 15.07.2026 · 111 (8) · 2101-2144
DOI: 10.1210/clinem/dgag168 ↗Kurz gefasst
Leitlinie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 13.06.2026. Verfasst von Ana Claudia Latronico und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Clinical Hospital, São Paulo Medical School, University of São Paulo, São Paulo 05403 900, Brazil. Hauptthemen laut MEDLINE: Puberty, Precocious, Endocrinology. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 234 Literaturangaben. Gefördert von: Endocrine Society.
Abstract (Originalsprache)
Background
Central precocious puberty (CPP), which is traditionally defined as the development of secondary sexual characteristics before age 8 years in girls and age 9 years in boys, results from the premature activation of the hypothalamic–pituitary–gonadal (HPG) axis. CPP can be associated with short adult stature, adverse psychosocial outcomes, and increased cardiometabolic and cancer risks in adulthood. Gonadotropin-releasing hormone (GnRH) agonists can effectively suppress premature activation of the HPG axis and have the potential to increase adult height as well as improve psychosocial and long-term health outcomes among patients with CPP. However, as secular trends have continued to shift toward earlier age of pubertal onset, some subpopulations of children with CPP, as it is currently defined, may not require the same extent of diagnostic evaluation and treatment.
Objective
Develop evidence-based recommendations related to the diagnosis and treatment of CPP.
Methods
A multidisciplinary panel of clinical experts, along with experts in guideline methodology and systematic literature review, used the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach to address 10 clinical questions related to the diagnosis and treatment of CPP. Systematic reviews of health-related benefits and harms were conducted for each clinical question. The guideline development panel (GDP) also used the GRADE evidence-to-decision (EtD) framework to address stakeholder values and preferences, costs and required resources, cost-effectiveness, acceptability, feasibility, and potential impacts on health equity.
Results
In girls with thelarche (Tanner stage B2) between ages 7.0 and 8.0 years, the GDP suggests watchful waiting via periodic physical examinations (every 4-6 months) rather than immediately performing evaluation with laboratory testing or radiologic imaging. In addition, the GDP suggests that all girls with breast development (ie, Tanner stage B2) before age 7 years should first be observed for 4 to 6 months to differentiate unsustained or slowly progressive puberty vs rapidly progressive puberty. These recommendations are largely based on evidence that girls with slowly progressive puberty attain a normal adult height without treatment. When hormonal evaluation is performed to confirm central (GnRH-dependent) activation as the cause of precocious puberty, the GDP suggests starting the evaluation with ultrasensitive basal luteinizing hormone (LH) concentration rather than routine GnRH/GnRH agonist (GnRHa) stimulation testing for all patients. While brain magnetic resonance imaging has been a traditional part of CPP evaluation, the GDP suggests that it should not be routinely performed in girls ages 6.0 to 8.0 years and boys ages 8.0 to 9.0 years without central nervous system (eg, neuro-ophthalmologic) symptoms, largely based on a low prevalence of pathologic intracranial findings in these age groups. The GDP suggests against routine genetic testing for patients with CPP, although they judged that genetic testing (eg, MKRN3 sequencing) should be considered for patients with familial CPP through a shared decision-making process. The GDP suggests GnRHa treatment for many children with CPP, although available evidence suggests that some patient subgroups (eg, older girls with slowly progressive CPP) may be less likely to receive a net benefit with this treatment. Rather than always starting GnRHa treatment with a monthly injectable formulation, the GDP suggests that treatment should be initiated with the formulation (such as a longer-acting formulation) that is anticipated to be used long-term. The GDP suggests against routine addition of growth hormone therapy to increase adult height. They also suggest against the routine biochemical testing (eg, LH, sex steroids) to monitor pubertal suppression while receiving GnRHa, instead reserving biochemical testing to confirm clinically suspected treatment failure. Finally, the GDP suggests against routinely continuing GnRHa treatment beyond chronologic age 10.0 to 11.0 years (girls) or 11.0 to 12.0 years (boys) and/or bone age 11.0 to 12.0 years (girls) or 12.0 to 13.0 years (boys).
Conclusion
These clinical recommendations were developed to address important uncertainties in the diagnosis and treatment of children with CPP. They are based on the best available scientific evidence regarding clinical outcomes judged to be most important to patients and families. The GDP's overarching goal was to suggest diagnostic and therapeutic strategies that will most likely provide net clinical benefits while simultaneously considering important contextual factors such as cost and feasibility. The guideline-development process highlighted important knowledge gaps and the substantial need for additional research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology and Metabolism, Clinical Hospital, São Paulo Medical School, University of São Paulo, São Paulo 05403 900, Brazil.
- Division of Endocrinology, Boston Children's Hospital, Boston, MA 02115, USA.
- Department of Pharmacy, Children's Hospital Colorado, Aurora, CO 80045, USA.
- Department of Pediatrics and Pediatric Endocrinology, Hospital Infantil Universitario Niño Jesús, Research Institute La Princesa, Universidad Autónoma de Madrid, Centro de Investigación Biomédica en Red de Fisiopatologí…
- Pediatric Endocrinology Department, Robert-Debré Hospital, Paris Cité University, Paris 75019, France.
- Inserm U1141 NeuroDiderot, Paris City University, Paris F-75006, France.
ORCID-Profile: Ana Claudia Latronico, Stephanie A Roberts, Morgan Alonzo, Jesús Argente, Ana Pinheiro Machado Canton, Jean-Claude Carel, Fernando Cassorla, Evangelia Charmandari, Erica A Eugster, Anna Grandone, Anders Juul, Paul B Kaplowitz, Maria E Street, Christopher R McCartney
Förderung
- Endocrine Society
Zitieren
APA
Latronico, A. C., Roberts, S. A., Alonzo, M., Argente, J., Canton, A. P. M., Carel, J. C., Cassorla, F., Charmandari, E., Eugster, E. A., Grandone, A., Greenspan, L. C., Hawse, E. C., Juul, A., Kaplowitz, P. B., Murad, M. H., Street, M. E., Walker, V., & McCartney, C. R. (2026). Central precocious puberty: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 111(8), 2101-2144. https://doi.org/10.1210/clinem/dgag168
Vancouver
Latronico AC, Roberts SA, Alonzo M, Argente J, Canton APM, Carel JC, et al. Central precocious puberty: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2026;111(8):2101-2144. doi:10.1210/clinem/dgag168
BibTeX
@article{Latronico2026,
author = {Latronico, Ana Claudia and Roberts, Stephanie A and Alonzo, Morgan and Argente, Jesús and Canton, Ana Pinheiro Machado and Carel, Jean-Claude and Cassorla, Fernando and Charmandari, Evangelia and Eugster, Erica A and Grandone, Anna and Greenspan, Louise C and Hawse, Elizabeth C and Juul, Anders and Kaplowitz, Paul B and Murad, M Hassan and Street, Maria E and Walker, Vayana and McCartney, Christopher R},
title = {Central precocious puberty: an Endocrine Society clinical practice guideline},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
volume = {111},
number = {8},
pages = {2101--2144},
doi = {10.1210/clinem/dgag168}
}
EUVIMED